Nothofagin
Catalog No: CFN92888
Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases. Nothofagin may have significant benefits in the treatment of diabetic complications. Nothofagin has potential to as an anti-sendothelial cell protein C receptor shedding reagent against phorbol-12-myristate 13-acetate and cecal ligation and puncture -mediated endothelial cell protein C receptor shedding.
Alliin
Catalog No: CFN93533
Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase, hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. Alliin has anti-inflammatory activity, it protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response; alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. Alliin and sabinene have detectable levels of antimicrobial activity.